(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
(攻击)2:细胞和体液免疫基因工程治愈艾滋病毒
基本信息
- 批准号:10614633
- 负责人:
- 金额:$ 284.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-07 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAddressAdverse effectsAnimal ModelAntibody FormationAutologousB-LymphocytesBerlinBindingBiodistributionBiologyBloodCCR5 geneCell TransplantationCellsCellular ImmunityCentral Nervous SystemClinical ResearchComplementDevelopmentDifferentiated GeneDiseaseDrug or chemical Tissue DistributionElementsEngineered GeneEngineeringEngraftmentFred Hutchinson Cancer Research CenterGene CombinationsGene DeliveryGene ModifiedGeneticGenetic EngineeringGrantHIVHIV-1Hematopoietic Stem Cell TransplantationHematopoietic stem cellsHighly Active Antiretroviral TherapyHomologous TransplantationHumanHumoral ImmunitiesImmuneImmunityImmunologyImmunotherapeutic agentImmunotherapyInfantInfectionInjectionsLentivirus VectorLondonMacaca mulattaMalignant NeoplasmsMediatingMembrane FusionModelingPatientsPhase I/II Clinical TrialPhase I/II TrialPlasmaPopulationPublishingReagentSafetySiteT cell therapyT-LymphocyteTechnologyTestingTherapeuticTherapeutic StudiesTissuesTransgenesTransplantationTreatment EfficacyUniversitiesVariantViralViremiaVirusWashingtonWorkadaptive immune responsearmcell behaviorcellular engineeringchimeric antigen receptorchimeric antigen receptor T cellschronic infectionclinical trial implementationcombination gene therapyengineered T cellsexperiencegene therapygene transplantation for gene therapyhumanized mouseimmune functionin vivoinhibitorknock-downlatent HIV reservoirneutralizing antibodynonhuman primatenovelpreclinical developmentprogramsresponsesimian human immunodeficiency virussmall hairpin RNAstem cell biologysuccesstargeted deliverytherapeutic genetumorvector
项目摘要
Overall: Project Summary/Abstract
The hypothesis to be tested in our U19 Program Project is that combining therapies of gene-engineered cellular
(chimeric antigen receptor (CAR)) and humoral (broadly neutralizing antibodies (bNAb)) immune reagents will
lead to a cure of HIV-1 disease. In the single remarkable case of the “Berlin patient”, allogeneic transplant of
CCR5Δ32 donor cells resulted in a functional cure without evidence for remaining HIV-1. However, a universal
unresolved limitation of transplant of gene-engineered hematopoietic stem/progenitor cells (HSPC) has been the
difficulty of achieving engraftment levels sufficient to provide good therapeutic efficacy. We propose here to focus
on building gene-engineered cellular and humoral immune therapeutics. One approach is a CAR recognizing
HIV-1 infected cells. T cell immunotherapy with tumor specific CARs delivered by adoptive T cell therapy has
proven to be effective against cancer in early human studies. We hypothesize that HSPC based delivery of CAR-
T cells can enhance the number and functional responses of the resultant engineered T cells. To complement
the engineering of T cell-mediated immunity, we also propose to engineer B cells to express bNAbs modified as
single chain variants (scFv-Fc bNAb). BNAbs directed to HIV-1 have shown promise at suppressing viremia in
animal models and clearing SHIV from the blood and tissues of infant rhesus macaques and human clinical
studies show effective suppression. Nonetheless, bNAbs require multiple injections to maintain levels required
to suppress virus in plasma and have not cleared virus in chronic infection. We will use novel lentiviral vectors
gene-engineered to target delivery of scFv-Fc bNAb into B cells in vivo without ex vivo manipulation. We
hypothesize that this strategy will promote bNAb production, biodistribution and activation/differentiation of gene-
modified B cells to clear HIV-1 reservoirs. Finally, success of these gene-modifying therapeutics depends upon
achieving sufficient systemic levels of gene-modified cells. Thus, another project will specifically address means
to modulate up or down the levels of gene-modified cells to achieve maximum therapeutic efficacy. In addition,
should any adverse effects be observed, the same reagent can be used to quickly eliminate gene-modified cells,
providing a “kill-switch”, and thus an added safety element to the overall approach.
Drs. Kitchen and Chen (UCLA) will serve as dual-PIs. Both have extensive experience in general stem cell
biology and its applications to HIV-1 disease. The Project/Core Leaders have expertise in HIV-1 biology and
gene therapeutic approaches to HIV-1 disease. The breadth of expertise ranges from vector and transgene
development (Chen, An, Morizono, Kitchen, Symonds), development and use of animal models for HSPC biology
(Kitchen, An, Morizono, Chen, Kiem), anti-HIV-1 immune function (Yang, Kitchen), understanding of HSPC
behavior (Chen) to clinical trial implementation (Symonds).
总体:项目摘要/摘要
在我们的U19计划项目中要检验的假设是,基因工程细胞的联合疗法
(嵌合抗原受体(CAR))和体液(广谱中和抗体(BNAb))免疫试剂将
导致HIV-1疾病的治愈。在一个引人注目的“柏林病人”的案例中,异基因移植的
CCR5HIV-32供体细胞在没有残留Δ-1证据的情况下获得了功能性治愈。然而,一个万能的
基因工程造血干/祖细胞(HSPC)移植的局限性尚未解决
难以达到足以提供良好治疗效果的植入水平。我们建议在这里集中精力
关于建立基因工程细胞和体液免疫疗法。一种方法是汽车识别
HIV-1感染细胞。通过过继T细胞疗法提供的肿瘤特异性CARS的T细胞免疫疗法
在早期的人类研究中被证明对癌症有效。我们假设基于HSPC的汽车交付-
T细胞可以增强所产生的工程化T细胞的数量和功能反应。来补充
在T细胞介导的免疫工程方面,我们还提出了工程B细胞来表达修饰为
单链变异体(scFv-Fc bNAb)。针对HIV-1的bNAb在抑制病毒血症方面显示出希望
幼年恒河猴和人类血液和组织中SIV的动物模型及清除
研究表明,抑制效果很好。尽管如此,bNAbs需要多次注射才能维持所需水平
抑制血浆中病毒并未清除慢性感染中的病毒。我们将使用新型慢病毒载体
基因工程的目的是将ScFv-Fc bNAb靶向体内的B细胞,而无需体外操作。我们
假设这一策略将促进bNAb的产生、生物分布和基因的激活/分化。
改良B细胞以清除HIV-1病毒储备库。最后,这些基因修饰疗法的成功取决于
达到足够的系统水平的转基因细胞。因此,另一个项目将专门处理手段
调节转基因细胞的水平,以达到最大的治疗效果。此外,
如果观察到任何不良反应,可以使用相同的试剂来快速消除转基因细胞,
提供了一个“终止开关”,从而为整个方法增加了一个安全元素。
Kitchen博士和Chen博士(加州大学洛杉矶分校)将担任双PI。两人在普通干细胞领域都有丰富的经验。
生物学及其在HIV-1疾病中的应用。项目/核心领导拥有艾滋病毒-1生物学和
HIV-1疾病的基因治疗方法。专业知识的范围从载体到转基因都有。
HSPC生物学动物模型的开发(Chen,An,Morizono,Kitchen,Symonds)
(厨房,安,Morizono,Chen,Kiem),抗HIV-1免疫功能(杨,厨房),了解HSPC
Behavior(Chen)到临床试验实施(Symonds)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IRVIN S.Y. CHEN其他文献
IRVIN S.Y. CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IRVIN S.Y. CHEN', 18)}}的其他基金
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
(攻击)2:细胞和体液免疫基因工程治愈艾滋病毒
- 批准号:
10468647 - 财政年份:2020
- 资助金额:
$ 284.81万 - 项目类别:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
(攻击)2:细胞和体液免疫基因工程治愈艾滋病毒
- 批准号:
10160814 - 财政年份:2020
- 资助金额:
$ 284.81万 - 项目类别:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
(攻击)2:细胞和体液免疫基因工程治愈艾滋病毒
- 批准号:
9890819 - 财政年份:2020
- 资助金额:
$ 284.81万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 284.81万 - 项目类别:
Research Grant